280 related articles for article (PubMed ID: 24961505)
1. Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma.
Chen YH; Huang CH; Lu HI; Chen CH; Huang WT; Hsieh MJ; Rau KM; Chang AY; Lin WC; Li SH
J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1185-92. PubMed ID: 24961505
[TBL] [Abstract][Full Text] [Related]
2. How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?
Kim ST; Park KH; Oh SC; Seo JH; Kim JS; Shin SW; Kim YH
Oncology; 2012; 83(6):354-60. PubMed ID: 23052034
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer.
Yuge K; Miyajima A; Tanaka N; Shirotake S; Kosaka T; Kikuchi E; Oya M
Ann Surg Oncol; 2012 Nov; 19(12):3987-93. PubMed ID: 22872290
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with abdominal aortic aneurysms: nation-wide cohort study.
Kristensen KE; Torp-Pedersen C; Gislason GH; Egfjord M; Rasmussen HB; Hansen PR
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):733-40. PubMed ID: 25633315
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have no beneficial effect on ablation outcome in chronic persistent atrial fibrillation.
Zheng B; Kang J; Tian Y; Tang R; Long D; Yu R; He H; Zhang M; Shi L; Tao H; Liu X; Dong J; Ma C
Acta Cardiol; 2009 Jun; 64(3):335-40. PubMed ID: 19593943
[TBL] [Abstract][Full Text] [Related]
6. Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC.
Miao L; Chen W; Zhou L; Wan H; Gao B; Feng Y
Sci Rep; 2016 Feb; 6():21359. PubMed ID: 26883083
[TBL] [Abstract][Full Text] [Related]
7. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine.
Nakai Y; Isayama H; Ijichi H; Sasaki T; Sasahira N; Hirano K; Kogure H; Kawakubo K; Yagioka H; Yashima Y; Mizuno S; Yamamoto K; Arizumi T; Togawa O; Matsubara S; Tsujino T; Tateishi K; Tada M; Omata M; Koike K
Br J Cancer; 2010 Nov; 103(11):1644-8. PubMed ID: 20978506
[TBL] [Abstract][Full Text] [Related]
11. Effect of direct renin inhibitor, aliskiren, on peripheral blood monocyte subsets and myocardial salvage in patients with primary acute myocardial infarction.
Ozaki Y; Imanishi T; Tanimoto T; Kashiwagi M; Tsujioka H; Sougawa H; Orii M; Shiono Y; Shimamura K; Ishibashi K; Komukai K; Ino Y; Kitabata H; Akasaka T
Circ J; 2012; 76(6):1461-8. PubMed ID: 22453004
[TBL] [Abstract][Full Text] [Related]
12. Renin-angiotensin system blocking drugs.
Robles NR; Cerezo I; Hernandez-Gallego R
J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):14-33. PubMed ID: 24038019
[TBL] [Abstract][Full Text] [Related]
13. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy.
Wilop S; von Hobe S; Crysandt M; Esser A; Osieka R; Jost E
J Cancer Res Clin Oncol; 2009 Oct; 135(10):1429-35. PubMed ID: 19399518
[TBL] [Abstract][Full Text] [Related]
14. Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy.
Neutel JM
Curr Med Res Opin; 2010 Jan; 26(1):213-22. PubMed ID: 19921961
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH
J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170
[TBL] [Abstract][Full Text] [Related]
16. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis.
Tandon P; Abraldes JG; Berzigotti A; Garcia-Pagan JC; Bosch J
J Hepatol; 2010 Aug; 53(2):273-82. PubMed ID: 20570385
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin I-converting enzyme inhibitors/angiotensin II receptor blockers may reduce tumor recurrence in left-sided and early colorectal cancers.
Ozawa T; Hashiguchi Y; Yagi T; Fukushima Y; Shimada R; Hayama T; Tsuchiya T; Nozawa K; Iinuma H; Ishihara S; Matsuda K
Int J Colorectal Dis; 2019 Oct; 34(10):1731-1739. PubMed ID: 31478086
[TBL] [Abstract][Full Text] [Related]
18. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
Burchill LJ; Velkoska E; Dean RG; Griggs K; Patel SK; Burrell LM
Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC
PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
[TBL] [Abstract][Full Text] [Related]
20. Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs.
Yang Y; Thumula V; Pace PF; Banahan BF; Wilkin NE; Lobb WB
J Am Pharm Assoc (2003); 2010; 50(4):527-31. PubMed ID: 20621872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
